title: Hypoglycemic effects of vanadium on alloxan monohydrate induced diabetic dogs.
abstract: The hypoglycemic effects after oral administration of vanadium have been studied previously in many species such as rats, mice and even humans. However, there has been no prior report on the glucose lowering effect of vanadium on diabetic dogs. Therefore, the purpose of this study was to evaluate the hypoglycemic effects of oral vanadium on diabetic dogs. Diabetes mellitus in the dogs studied was induced by alloxan monohydrate intravenous injection. The dogs were divided into two groups, one was the diabetic control (DC) group (n = 4) and the other was the vanadium treated (DV) group (n = 6). Fresh water was supplied to the dogs in the DC group, but sodium metavanadate solution (0.1approximately 0.2 mg/ml) was given to the dogs in DV group from one week after the alloxan injection. The fasting glucose levels, fructosamine and serum chemistry profiles were compared between the two groups weekly for three weeks. The fasting blood glucose levels in DV group were significantly lower than those in the DC group (p < 0.01). Fructosamine levels in the DV group were also lower than those in the DC group (p < 0.05). The serum chemistry profiles were not significantly different in comparisons between the two groups. However, the cholesterol levels were significantly lower in the DV group compared to the DC group (p < 0.05). Our findings showed that oral vanadium administration had a hypoglycemic effect on chemically induced diabetic dogs.
authors.affiliation: Department of Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea.
authors.forename: Joo-Min
authors.initials: JM
authors.lastname: Kim
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Chung
authors.forename: Sook-Yeon
authors.initials: SY
authors.lastname: Lee
authors.forename: Eun-Wha
authors.initials: EW
authors.lastname: Choi
authors.forename: Min-Kyu
authors.initials: MK
authors.lastname: Kim
authors.forename: Cheol-Yong
authors.initials: CY
authors.lastname: Hwang
authors.forename: Hwa-Young
authors.initials: HY
authors.lastname: Youn
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D002712:Chlorides / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D019270:Fructosamine / Q000097:blood; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000473:pathology; D011188:Potassium / Q000097:blood; D011897:Random Allocation; D012964:Sodium / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014638:Vanadates / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D002712:Chlorides; D007004:Hypoglycemic Agents; D014280:Triglycerides; D014638:Vanadates; D019270:Fructosamine; D002784:Cholesterol; D012964:Sodium; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D011188:Potassium